JP2020521774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521774A5 JP2020521774A5 JP2019565504A JP2019565504A JP2020521774A5 JP 2020521774 A5 JP2020521774 A5 JP 2020521774A5 JP 2019565504 A JP2019565504 A JP 2019565504A JP 2019565504 A JP2019565504 A JP 2019565504A JP 2020521774 A5 JP2020521774 A5 JP 2020521774A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- combination
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2017/086624 | 2017-05-31 | ||
| CN2017086624 | 2017-05-31 | ||
| PCT/IB2018/053839 WO2018220546A1 (en) | 2017-05-31 | 2018-05-30 | Crystalline forms of 5-bromo-2,6-di(1 h-pyrazol-1-yl)pyrimidin-4-amine and new salts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020521774A JP2020521774A (ja) | 2020-07-27 |
| JP2020521774A5 true JP2020521774A5 (https=) | 2021-07-26 |
| JP7273732B2 JP7273732B2 (ja) | 2023-05-15 |
Family
ID=62778954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565504A Active JP7273732B2 (ja) | 2017-05-31 | 2018-05-30 | ５－ブロモ－２，６－ジ（１ｈ－ピラゾール－１－イル）ピリミジン－４－アミン及び新たな塩の結晶形 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10933064B2 (https=) |
| EP (1) | EP3630751B1 (https=) |
| JP (1) | JP7273732B2 (https=) |
| KR (1) | KR20200018503A (https=) |
| CN (1) | CN110944995B (https=) |
| AR (1) | AR111906A1 (https=) |
| AU (1) | AU2018277241B2 (https=) |
| BR (1) | BR112019025149A2 (https=) |
| CA (1) | CA3065475A1 (https=) |
| CL (2) | CL2019003468A1 (https=) |
| IL (2) | IL270795B2 (https=) |
| JO (1) | JOP20190279B1 (https=) |
| MX (1) | MX2021014104A (https=) |
| PH (1) | PH12019502703A1 (https=) |
| RU (2) | RU2019138329A (https=) |
| TW (1) | TWI814725B (https=) |
| WO (1) | WO2018220546A1 (https=) |
| ZA (1) | ZA201907610B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017106656A1 (en) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| AU2018277241B2 (en) * | 2017-05-31 | 2021-03-04 | Novartis Ag | Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1- yl)pyrimidin-4-amine and new salts |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL129299A0 (en) | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
| JP4064671B2 (ja) * | 2000-02-25 | 2008-03-19 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体モジュレーター |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| JP2007514003A (ja) | 2003-12-15 | 2007-05-31 | アルミラル プロデスファルマ アーゲー | アデノシン受容体アンタゴニストとしての２，６−ビスヘテロアリール−４−アミノピリミジン |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2644996A1 (en) * | 2006-03-02 | 2007-09-13 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
| WO2008110891A2 (en) | 2007-03-09 | 2008-09-18 | Orchid Research Laboratories Limited, | New heterocyclic compounds |
| US8153064B2 (en) | 2007-03-22 | 2012-04-10 | Doebler Ii Robert W | Systems and devices for isothermal biochemical reactions and/or analysis |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| ES2365960B1 (es) | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| JP6240600B2 (ja) | 2011-07-24 | 2017-11-29 | キュアテク リミテッド | ヒト化免疫モノクローナル抗体の変異体 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| SI3334431T1 (sl) * | 2015-08-11 | 2020-01-31 | Novartis Ag | 5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju raka |
| DK3579874T3 (da) * | 2017-02-10 | 2021-10-11 | Novartis Ag | 1-(4-amino-5-brom-6-(1h-pyrazol-1-yl)pyrimidin-2-yl)-1h-pyrazol-4-ol og anvendelse deraf til behandling af cancer |
| AU2018277241B2 (en) * | 2017-05-31 | 2021-03-04 | Novartis Ag | Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1- yl)pyrimidin-4-amine and new salts |
-
2018
- 2018-05-30 AU AU2018277241A patent/AU2018277241B2/en not_active Ceased
- 2018-05-30 CA CA3065475A patent/CA3065475A1/en active Pending
- 2018-05-30 WO PCT/IB2018/053839 patent/WO2018220546A1/en not_active Ceased
- 2018-05-30 BR BR112019025149-9A patent/BR112019025149A2/pt not_active IP Right Cessation
- 2018-05-30 IL IL270795A patent/IL270795B2/en unknown
- 2018-05-30 RU RU2019138329A patent/RU2019138329A/ru unknown
- 2018-05-30 JO JOJO/P/2019/0279A patent/JOP20190279B1/ar active
- 2018-05-30 EP EP18734945.1A patent/EP3630751B1/en active Active
- 2018-05-30 CN CN201880035190.7A patent/CN110944995B/zh active Active
- 2018-05-30 US US16/616,844 patent/US10933064B2/en not_active Expired - Fee Related
- 2018-05-30 KR KR1020197038580A patent/KR20200018503A/ko not_active Ceased
- 2018-05-30 PH PH1/2019/502703A patent/PH12019502703A1/en unknown
- 2018-05-30 RU RU2022102355A patent/RU2022102355A/ru unknown
- 2018-05-30 JP JP2019565504A patent/JP7273732B2/ja active Active
- 2018-05-30 IL IL291721A patent/IL291721B2/en unknown
- 2018-05-31 AR ARP180101452A patent/AR111906A1/es unknown
- 2018-05-31 TW TW107118638A patent/TWI814725B/zh not_active IP Right Cessation
-
2019
- 2019-11-18 ZA ZA2019/07610A patent/ZA201907610B/en unknown
- 2019-11-27 MX MX2021014104A patent/MX2021014104A/es unknown
- 2019-11-27 CL CL2019003468A patent/CL2019003468A1/es unknown
-
2021
- 2021-01-25 US US17/156,785 patent/US11654144B2/en active Active
- 2021-10-12 CL CL2021002667A patent/CL2021002667A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260021178A1 (en) | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor | |
| JP7250724B2 (ja) | 抗ｈｅｒ２抗体及び免疫複合体 | |
| CN111801334B (zh) | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 | |
| TWI826828B (zh) | 抗her3抗體-藥物結合物及含有其之醫藥及醫藥組成物 | |
| AU2016306090B2 (en) | 5-bromo-2,6-di-(1H-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| JP2017186337A5 (https=) | ||
| JP2021525087A5 (https=) | ||
| TW202122115A (zh) | 包含抗人類ｒｏｒ１抗體之抗體—藥物結合物及其用途 | |
| JP2018503365A5 (https=) | ||
| RU2019138337A (ru) | Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии | |
| CN110087730A (zh) | 使用包含parp抑制剂的组合产品治疗癌症 | |
| IL263466B2 (en) | Anti-CD3 antibodies and methods of using them | |
| JP2022116269A5 (https=) | ||
| WO2024051796A1 (en) | Albumin binding proteins, fusion proteins and uses thereof | |
| CN107148285A (zh) | 吡咯并苯并二氮杂*‑抗体缀合物 | |
| JP2013519364A5 (https=) | ||
| JP2021511372A5 (https=) | ||
| JP2020521774A5 (https=) | ||
| JP2019524714A5 (https=) | ||
| JP2021531255A5 (https=) | ||
| RU2019138329A (ru) | Кристаллические формы 5-бром-2,6-ди(1н-пиразол-1-ил)пиримидин-4-амина и новых солей | |
| JP2021518348A5 (https=) | ||
| CN120000805A (zh) | 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途 | |
| TW202509062A (zh) | 抗b7-h3抗體及其用途 | |
| JP2020507569A5 (https=) |